• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

协调调控线粒体拓扑异构酶 IB 与线粒体核编码基因和 MYC。

Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.

机构信息

Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20890, USA.

出版信息

Nucleic Acids Res. 2011 Aug;39(15):6620-32. doi: 10.1093/nar/gkr208. Epub 2011 Apr 29.

DOI:10.1093/nar/gkr208
PMID:21531700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3159436/
Abstract

Mitochondrial DNA (mtDNA) is entirely dependent on nuclear genes for its transcription and replication. One of these genes is TOP1MT, which encodes the mitochondrial DNA topoisomerase IB, involved in mtDNA relaxation. To elucidate TOP1MT regulation, we performed genome-wide profiling across the 60-cell line panel (the NCI-60) of the National Cancer Institute Developmental Therapeutics Program. We show that TOP1MT mRNA expression varies widely across these cell lines with the highest levels in leukemia (HL-60, K-562) and melanoma (SK-MEL-28), intermediate levels in breast (MDA-MB-231), ovarian (OVCAR) and colon (HCT-116, HCT-15, KM-12), and lowest levels in renal (ACHN, A498), prostate (PC-3, DU-145) and central nervous system cell lines (SF-539, SF-268, SF-295). Genome-wide analyses show that TOP1MT expression is significantly correlated with the other mitochondrial nuclear-encoded genes including the mitochondrial nucleoid genes, and demonstrate an overall co-regulation of the mitochondrial nuclear-encoded genes. We also find very high correlation between the expression of TOP1MT and the proto-oncogene MYC (c-myc). TOP1MT contains E-boxes (c-myc binding sites) and TOP1MT transcription follows MYC up- and down-regulation by MYC promoter activation and siRNA against MYC. Our finding implicates MYC as a novel regulator of TOP1MT and confirms its role as a master regulator of MNEGs and mitochondrial nucleoids.

摘要

线粒体 DNA(mtDNA)的转录和复制完全依赖于核基因。这些基因中的一个是 TOP1MT,它编码线粒体 DNA 拓扑异构酶 IB,参与 mtDNA 的松弛。为了阐明 TOP1MT 的调控机制,我们在国立癌症研究所发展治疗学计划的 60 细胞系面板(NCI-60)上进行了全基因组分析。我们表明,TOP1MT mRNA 表达在这些细胞系中差异很大,白血病(HL-60、K-562)和黑色素瘤(SK-MEL-28)中的表达水平最高,乳腺癌(MDA-MB-231)、卵巢癌(OVCAR)和结肠癌(HCT-116、HCT-15、KM-12)中的表达水平中等,而在肾癌(ACHN、A498)、前列腺癌(PC-3、DU-145)和中枢神经系统细胞系(SF-539、SF-268、SF-295)中的表达水平最低。全基因组分析表明,TOP1MT 的表达与其他线粒体核编码基因,包括线粒体核区基因显著相关,并证明了线粒体核编码基因的整体协同调控。我们还发现 TOP1MT 表达与原癌基因 MYC(c-myc)之间存在非常高的相关性。TOP1MT 含有 E-Boxes(c-myc 结合位点),TOP1MT 的转录遵循 MYC 的上调和下调,由 MYC 启动子的激活和针对 MYC 的 siRNA 调节。我们的发现表明 MYC 是 TOP1MT 的一个新的调控因子,并证实了它作为 MNEGs 和线粒体核区的主要调控因子的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/25fdc375de0e/gkr208f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/ce8c6e19302e/gkr208f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/eb860ed1cd2a/gkr208f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/25fdc375de0e/gkr208f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/ce8c6e19302e/gkr208f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/eb860ed1cd2a/gkr208f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bb4/3159436/25fdc375de0e/gkr208f3.jpg

相似文献

1
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.协调调控线粒体拓扑异构酶 IB 与线粒体核编码基因和 MYC。
Nucleic Acids Res. 2011 Aug;39(15):6620-32. doi: 10.1093/nar/gkr208. Epub 2011 Apr 29.
2
Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription.转录谱分析表明,线粒体拓扑异构酶IB作为线粒体DNA转录的拓扑屏障和调节因子发挥作用。
J Biol Chem. 2017 Dec 8;292(49):20162-20172. doi: 10.1074/jbc.M117.815241. Epub 2017 Oct 11.
3
Beyond the unwinding: role of TOP1MT in mitochondrial translation.超越解旋:TOP1MT 在线粒体翻译中的作用。
Cell Cycle. 2019 Oct;18(19):2377-2384. doi: 10.1080/15384101.2019.1646563. Epub 2019 Aug 9.
4
Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt).用一种有毒的线粒体拓扑异构酶 I(Top1mt)来绘制线粒体 DNA 的拓扑异构酶位点。
J Biol Chem. 2014 Jun 27;289(26):18595-602. doi: 10.1074/jbc.M114.555367. Epub 2014 May 5.
5
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.TOP1MT 单核苷酸变异的分布偏倚和生化特征。
Sci Rep. 2017 Aug 17;7(1):8614. doi: 10.1038/s41598-017-09258-2.
6
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.线粒体型 IB 拓扑异构酶驱动线粒体翻译和致癌作用。
Nat Commun. 2019 Jan 8;10(1):83. doi: 10.1038/s41467-018-07922-3.
7
Functional characterization of two variants of mitochondrial topoisomerase TOP1MT that impact regulation of the mitochondrial genome.鉴定两种线粒体拓扑异构酶 TOP1MT 变异体的功能,这两种变异体影响线粒体基因组的调控。
J Biol Chem. 2022 Oct;298(10):102420. doi: 10.1016/j.jbc.2022.102420. Epub 2022 Aug 24.
8
Mitochondrial topoisomerases and alternative splicing of the human TOP1mt gene.线粒体拓扑异构酶与人TOP1mt基因的可变剪接
Biochimie. 2007 Apr;89(4):474-81. doi: 10.1016/j.biochi.2006.11.002. Epub 2006 Nov 27.
9
Poisoning of mitochondrial topoisomerase I by lamellarin D.Lamellarin D 致线粒体拓扑异构酶 I 中毒。
Mol Pharmacol. 2014 Aug;86(2):193-9. doi: 10.1124/mol.114.092833. Epub 2014 Jun 2.
10
Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA.线粒体DNA调控性D环区域中的线粒体拓扑异构酶I位点。
Biochemistry. 2008 Oct 28;47(43):11196-203. doi: 10.1021/bi800774b. Epub 2008 Oct 1.

引用本文的文献

1
A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma.一种新型的 CREB5/TOP1MT 轴通过抑制头颈鳞状细胞癌中的线粒体凋亡来赋予顺铂耐药性。
BMC Med. 2022 Jul 1;20(1):231. doi: 10.1186/s12916-022-02409-x.
2
Human topoisomerases and their roles in genome stability and organization.人类拓扑异构酶及其在基因组稳定性和组织中的作用。
Nat Rev Mol Cell Biol. 2022 Jun;23(6):407-427. doi: 10.1038/s41580-022-00452-3. Epub 2022 Feb 28.
3
The mitochondrial landscape of ovarian cancer: emerging insights.

本文引用的文献

1
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.NCI 60 细胞系筛选的全基因组 mRNA 和 microRNA 分析及 FdUMP[10]与氟尿嘧啶、氟尿苷和拓扑异构酶 1 抑制剂的比较。
Mol Cancer Ther. 2010 Dec;9(12):3105-14. doi: 10.1158/1535-7163.MCT-10-0674.
2
Identification of rare DNA variants in mitochondrial disorders with improved array-based sequencing.采用改良的基于阵列的测序技术鉴定线粒体疾病中的罕见 DNA 变体。
Nucleic Acids Res. 2011 Jan;39(1):44-58. doi: 10.1093/nar/gkq750. Epub 2010 Sep 15.
3
Mitochondrial DNA mutations in disease and aging.
卵巢癌的线粒体格局:新见解
Carcinogenesis. 2021 May 28;42(5):663-671. doi: 10.1093/carcin/bgab033.
4
Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.乳腺癌和前列腺癌存在常见的体细胞拷贝数改变,这些改变在不同种族之间存在一致性差异,并与生存相关。
BMC Med Genomics. 2020 Aug 20;13(1):116. doi: 10.1186/s12920-020-00765-2.
5
Beyond the unwinding: role of TOP1MT in mitochondrial translation.超越解旋:TOP1MT 在线粒体翻译中的作用。
Cell Cycle. 2019 Oct;18(19):2377-2384. doi: 10.1080/15384101.2019.1646563. Epub 2019 Aug 9.
6
KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.KRAS 依赖性的 MYC 抑制增强了癌细胞对细胞毒性药物的敏感性。
Oncotarget. 2017 Mar 14;8(11):17995-18009. doi: 10.18632/oncotarget.14929.
7
Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.线粒体拓扑异构酶I(TOP1mt)的缺失会损害肝脏再生。
Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11282-7. doi: 10.1073/pnas.1511016112. Epub 2015 Aug 24.
8
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.使用CellMiner 1.6进行NCI-60的系统药理学和基因组分析。
Clin Cancer Res. 2015 Sep 1;21(17):3841-52. doi: 10.1158/1078-0432.CCR-15-0335. Epub 2015 Jun 5.
9
MYC and mitochondrial biogenesis.MYC与线粒体生物合成
Cold Spring Harb Perspect Med. 2014 May 1;4(5):a014225. doi: 10.1101/cshperspect.a014225.
10
Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.对JAK2 V617F和MPL W515 K/L阴性的原发性血小板增多症患者进行SESN2、DNAJC17、ST13、TOP1MT和NTRK1基因突变检测。
Br J Haematol. 2014 Jun;165(5):734-7. doi: 10.1111/bjh.12790. Epub 2014 Feb 26.
疾病与衰老中的线粒体 DNA 突变。
Environ Mol Mutagen. 2010 Jun;51(5):440-50. doi: 10.1002/em.20586.
4
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.DNA拓扑异构酶及其被抗癌和抗菌药物抑制的情况。
Chem Biol. 2010 May 28;17(5):421-33. doi: 10.1016/j.chembiol.2010.04.012.
5
Targeting mitochondria for cancer therapy.针对线粒体的癌症治疗方法。
Nat Rev Drug Discov. 2010 Jun;9(6):447-64. doi: 10.1038/nrd3137. Epub 2010 May 14.
6
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.分析美国国立癌症研究所(NCI)60 人肿瘤细胞系panel 中食品和药物管理局批准的抗癌药物。
Mol Cancer Ther. 2010 May;9(5):1451-60. doi: 10.1158/1535-7163.MCT-10-0106. Epub 2010 May 4.
7
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.NCI-60 综合药物活性的 mRNA 和 microRNA 表达谱。
Mol Cancer Ther. 2010 May;9(5):1080-91. doi: 10.1158/1535-7163.MCT-09-0965. Epub 2010 May 4.
8
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.NCI-60 中的外显子阵列分析揭示了转录在第一个内含子的鸟嘌呤四联体处暂停对 TOP1 的潜在调控。
Cancer Res. 2010 Mar 15;70(6):2191-203. doi: 10.1158/0008-5472.CAN-09-3528. Epub 2010 Mar 9.
9
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.NCI 60 肿瘤细胞系集中的蛋白质组学特征、突变和药物反应性的综合分析。
Mol Cancer Ther. 2010 Feb;9(2):257-67. doi: 10.1158/1535-7163.MCT-09-0743. Epub 2010 Feb 2.
10
Functional organization of mammalian mitochondrial DNA in nucleoids: history, recent developments, and future challenges.哺乳动物线粒体 DNA 在核小体中的功能组织:历史、最新进展和未来挑战。
IUBMB Life. 2010 Jan;62(1):19-32. doi: 10.1002/iub.282.